Trial reportKidney international2019
Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone.
Trial report in Kidney international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- SIRT5-Mediated Desuccinylation of ACAA2 Protects Against Calcium Oxalate-Induced Kidney Injury by Regulating Fatty Acid Oxidation to Suppress Mitochondrial Oxidative Injury and Ferroptosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- ACAA1 mediates arachidonic acid dysregulation and membrane phospholipid remodeling to promote crystal-cell adhesion and ferroptosis susceptibility in calcium oxalate kidney stone.Journal of pharmaceutical analysis · 2026Article
- Acute Effect of High Fat Intake on Urinary Acidification Parameters.Kidney international reports · 2025Article
- 2bRAD-M Reveals the Characteristics of Urinary Microbiota in Overweight Patients with Urinary Tract Stones.Biomedicines · 2025Article
- Article
- Pediatric adrenocortical carcinoma complicated by uric acid nephrolithiasis: a unique case report.BMC urology · 2025Article
- Analysis of microRNA expression in patients with uric acid calculi.Urolithiasis · 2025Article
- L-shaped association between the ratio of serum albumin to globulin and the risk of all-cause mortality among adults with kidney stones: a national cohort study.Translational andrology and urology · 2025Article
- Effects of antidiabetic drugs on the level of serum uric acid in patients who have type 2 diabetes.Saudi medical journal · 2025Review
- The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions.Current obesity reports · 2025Review
- Nephroprotective effect of pioglitazone in a Wistar rat model of adenine‑induced chronic kidney disease.Experimental and therapeutic medicine · 2024Article
- Narrative literature review of antidiabetic drugs' effect on hyperuricemia: elaborating actual data and mechanisms.Endocrine connections · 2024Review
- Pioglitazone-induced alterations of purine metabolism in healthy male subjects.Clinical and translational science · 2024Article
- HMG-CoA Reductase Inhibitors Suppress Monosodium Urate-Induced NLRP3 Inflammasome Activation through Peroxisome Proliferator-Activated Receptor-γ Activation in THP-1 Cells.Pharmaceuticals (Basel, Switzerland) · 2023Article
- The Management of Diabetes with Hyperuricemia: Can We Hit Two Birds with One Stone?Journal of inflammation research · 2023Review
- Risk factors of urinary calculi in men with gout.Clinical rheumatology · 2022Article
- Role of insulin resistance and the gut microbiome on urine oxalate excretion in ob/ob mice.Physiological reports · 2022Article
- UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Update on Uric Acid and the Kidney.Current rheumatology reports · 2022Review
- Uric Acid and Urate in Urolithiasis: The Innocent Bystander, Instigator, and Perpetrator.Seminars in nephrology · 2020Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Idiopathic uric acid nephrolithiasis is characterized by an overly acidic urine pH caused by the combination of increased acid production and inadequate buffering of urinary protons by ammonia. A large proportion of uric acid stone formers exhibit features of the metabolic syndrome. We previously demonstrated that thiazolidinediones improved the urinary biochemical profile in an animal model of the metabolic syndrome. In this proof-of-concept study, we examined whether the thiazolidinedione pioglitazone can also ameliorate the overly acidic urine in uric acid stone formers. Thirty-six adults with idiopathic uric acid nephrolithiasis were randomized to pioglitazone 30 mg/day or matching placebo for 24 weeks. At baseline and study end, participants underwent collection of blood and 24-hour urine in an inpatient research unit while consuming a fixed metabolic diet, followed by assessment of the ammoniagenic response to an acute oral acid load. Twenty-eight participants completed the study. Pioglitazone treatment improved features of the metabolic syndrome. Pioglitazone also reduced net acid excretion and increased urine pH (5.37 to 5.59), the proportion of net acid excreted as ammonium, and ammonium excretion in response to an acute acid load, whereas these parameters were unchanged with placebo. Treatment of patients with idiopathic uric acid nephrolithiasis with pioglitazone for 24 weeks led to a reduction in the acid load presented to the kidney and a more robust ammoniagenesis and ammonium excretion, resulting in significantly higher urine pH. Future studies should consider the impact of this targeted therapy on uric acid stone formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.